Dasatinib preferentially induces apoptosis by inhibiting Lyn kinase in nilotinib-resistant chronic myeloid leukemia cell line

Por Okabe, Seiichi, Tauchi, Tetsuzo, Tanaka, Yuko, Ohyashiki, Kazuma
Publicado em 2011

Combination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells

Por Okabe, Seiichi, Tauchi, Tetsuzo, Katagiri, Seiichiro, Tanaka, Yuko, Ohyashiki, Kazuma
Publicado em 2014

Anti-leukemic activity of axitinib against cells harboring the BCR-ABL T315I point mutation

Por Okabe, Seiichi, Tauchi, Tetsuzo, Tanaka, Yuko, Sakuta, Juri, Ohyashiki, Kazuma
Publicado no J Hematol Oncol (2015)

Efficacy of the polo-like kinase inhibitor rigosertib, alone or in combination with Abelson tyrosine kinase inhibitors, against break point cluster region-c-Abelson-positive leukem...

Por Okabe, Seiichi, Tauchi, Tetsuzo, Tanaka, Yuko, Sakuta, Juri, Ohyashiki, Kazuma
Publicado no Oncotarget (2015)

Combination therapy with copanlisib and ABL tyrosine kinase inhibitors against Philadelphia chromosome-positive resistant cells

Por Okabe, Seiichi, Tauchi, Tetsuzo, Tanaka, Yuko, Sakuta, Juri, Ohyashiki, Kazuma
Publicado no Oncotarget (2016)

Age-related decrease of miRNA-92a levels in human CD8⁺T-cells correlates with a reduction of naïve T lymphocytes

Por Ohyashiki Michiyo, Ohyashiki Junko H, Hirota Ayako, Kobayashi Chiaki, Ohyashiki Kazuma
Publicado em 2011-11-01

A network biology approach evaluating the anticancer effects of bortezomib identifies SPARC as a therapeutic target in adult T-cell leukemia cells

Por Ohyashiki, Junko H, Hamamura, Ryoko, Kobayashi, Chiaki, Zhang, Yu, Ohyashiki, Kazuma
Publicado em 2008

Age-related decrease of miRNA-92a levels in human CD8(+ )T-cells correlates with a reduction of naïve T lymphocytes

Por Ohyashiki, Michiyo, Ohyashiki, Junko H, Hirota, Ayako, Kobayashi, Chiaki, Ohyashiki, Kazuma
Publicado em 2011

Exosomes Derived from Hypoxic Leukemia Cells Enhance Tube Formation in Endothelial Cells

Por Tadokoro, Hiroko, Umezu, Tomohiro, Ohyashiki, Kazuma, Hirano, Toshihiko, Ohyashiki, Junko H.
Publicado em 2013

Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cell...

Por Okabe, Seiichi, Tauchi, Tetsuzo, Tanaka, Yuko, Kimura, Shinya, Maekawa, Taira, Ohyashiki, Kazuma
Publicado em 2013

The C allele of JAK2 rs4495487 is an additional candidate locus that contributes to myeloproliferative neoplasm predisposition in the Japanese population

Por Ohyashiki, Junko H, Yoneta, Masayuki, Hisatomi, Hisashi, Iwabuchi, Tamiko, Umezu, Tomohiro, Ohyashiki, Kazuma
Publicado em 2012

Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1

Por Umezu, Tomohiro, Tadokoro, Hiroko, Azuma, Kenko, Yoshizawa, Seiichiro, Ohyashiki, Kazuma, Ohyashiki, Junko H.
Publicado no Blood (2014)

Down-Regulation of miR-92 in Human Plasma Is a Novel Marker for Acute Leukemia Patients

Por Tanaka, Masami, Oikawa, Kosuke, Takanashi, Masakatsu, Kudo, Motoshige, Ohyashiki, Junko, Ohyashiki, Kazuma, Kuroda, Masahiko
Publicado em 2009

Combining the ABL1 Kinase Inhibitor Ponatinib and the Histone Deacetylase Inhibitor Vorinostat: A Potential Treatment for BCR-ABL-Positive Leukemia

Por Okabe, Seiichi, Tauchi, Tetsuzo, Kimura, Shinya, Maekawa, Taira, Kitahara, Toshihiko, Tanaka, Yoko, Ohyashiki, Kazuma
Publicado em 2014

Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation

Por Okabe, Seiichi, Tauchi, Tetsuzo, Tanaka, Yuko, Kitahara, Toshihiko, Kimura, Shinya, Maekawa, Taira, Ohyashiki, Kazuma
Publicado em 2014

Impact on cell to plasma ratio of miR-92a in patients with acute leukemia: in vivo assessment of cell to plasma ratio of miR-92a

Por Ohyashiki, Junko H, Umezu, Tomohiro, Kobayashi, Chiaki, Hamamura, Ryoko S, Tanaka, Masami, Kuroda, Masahiko, Ohyashiki, Kazuma
Publicado em 2010

Downregulated microRNA-148b in circulating PBMCs in chronic myeloid leukemia patients with undetectable minimal residual disease: a possible biomarker to discontinue imatinib safel...

Por Ohyashiki, Junko H, Ohtsuki, Kazushige, Mizoguchi, Izuru, Yoshimoto, Takayuki, Katagiri, Seiichiro, Umezu, Tomohiro, Ohyashiki, Kazuma
Publicado em 2014

Expression Profile of a γ-Deletion Variant of the Human Telomerase Reverse Transcriptase Gene

Por Hisatomi, Hisashi, Ohyashiki, Kazuma, Ohyashiki, Junko H, Nagao, Kumi, Kanamaru, Taichi, Hirata, Hiroyuki, Hibi, Nozomu, Tsukada, Yutaka
Publicado em 2003

ELF4/MEF Activates MDM2 Expression and Blocks Oncogene-Induced p16 Activation To Promote Transformation

Por Sashida, Goro, Liu, Yan, Elf, Shannon, Miyata, Yasuhiko, Ohyashiki, Kazuma, Izumi, Miki, Menendez, Silvia, Nimer, Stephen D.
Publicado em 2009

Downregulation of Plasma miR-215 in Chronic Myeloid Leukemia Patients with Successful Discontinuation of Imatinib

Por Ohyashiki, Kazuma, Umezu, Tomohiro, Katagiri, Seiichiro, Kobayashi, Chiaki, Azuma, Kenko, Tauchi, Tetsuzo, Okabe, Seiichi, Fukuoka, Yutaka, Ohyashiki, Junko H.
Publicado no Int J Mol Sci (2016)